- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
In The Literature: NSAID/Statin Influence on PSA in High-Risk Prostate Cancer Patients
The study, published in Cancer Epidemiology, Biomarkers & Prevention, evaluated the influence of NSAIDs and statins on PSA levels in men with a high prostate cancer risk.
Using a population of 699 men, multiple linear regressions were used to investigate the associations between PSA and concomitant medications, and mixed-effects models were used to investigate these associations with PSAV.
After adjusting for selenium use, age, race, body mass index, and pack-years of smoking, aspirin, other NSAIDs, or statins did not demonstrate statistically significant associations with PSA (P = 0.79, 0.68, and 0.79, respectively) or PSAV (P = 0.23, 0.43, and 0.84, respectively). Results were not altered upon stratifying the sample between men who developed prostate cancer during the course of the study and those who did not.
Results from this study indicate that chronic use of aspirin, other NSAIDs, or statins did not affect PSA levels or PSAV in men at high risk for prostate cancer. Larger prospective studies designed to investigate these relationships are needed to confirm this result.
Link to the article: http://bit.ly/1rHlFf9
Source: Cancer Epidemiology, Biomarker & Prevention
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
